Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Peroxisome proliferator-activated receptors (PPAR) mediate inflammatory processes and alter cardiac function. However, it is not clear whether inflammatory cytokines or PPAR ligands regulate PPARs in the cardiomyocytes to modulate cardiac functions. We investigated the effects of tumour necrosis factor-alpha (TNF-α) and PPAR ligands on the expression of PPARs in HL-1 cardiomyocytes. Materials and methods: HL-1 cardiomyocytes were incubated with and without TNF-α (1, 10, 25 and 50 ng mL-1) or PPAR ligands (rosiglitazone, pioglitazone and fenofibrate) at concentrations of 0.1, 1 and 10 μm for 24 h. The cells also received SN-50 (NF-κB inhibitor, 50 μg mL-1), ascorbic acid (100 μm) and coenzyme Q10 (10 μm) alone or combined with TNF-α. Results: Using reverse transcriptase-polymerase chain reaction and Western blot, we found that incubation of TNF-α (50 ng mL-1) for 24 h decreased PPAR-α, but increased PPAR-γ without altering PPAR-δ. These effects were not changed by co-administration of SN-50. However, co-administration of ascorbic acid prevented the effect of TNF-α both on PPAR-α and PPAR-γ. Coenzyme Q10 partially attenuated the effect of TNF-α on PPAR-γ but did not alter its effect on PPAR-α. The administration of rosiglitazone (10 μm) and pioglitazone (10 μm) for 24 h increased PPAR-γ mRNA, but did not alter PPAR-α or PPAR-δ. Moreover, fenofibrate (0.1, 1 and 10 μm) increased PPAR-γ without any effects on PPAR-α or PPAR-δ. Conclusions: Oxidative stress causes the regulations of PPAR-α and PPAR-γ in the TNF-α-treated cardiomyocytes. The up-regulation of PPAR-γ by PPAR ligands may contribute to their anti-inflammation effects.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalEuropean Journal of Clinical Investigation
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Peroxisome Proliferator-Activated Receptors
Cytokines
Ligands
Tumor Necrosis Factor-alpha
coenzyme Q10
rosiglitazone
pioglitazone
Cardiac Myocytes
Fenofibrate
Ascorbic Acid

Keywords

  • Ascorbic acid
  • Coenzyme Q
  • Peroxisome proliferator-activated receptors
  • Tumour necrosis factor-alpha

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry
  • Biochemistry

Cite this

@article{e33b341b89484495937cfeb3e31ad0b4,
title = "Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors",
abstract = "Background: Peroxisome proliferator-activated receptors (PPAR) mediate inflammatory processes and alter cardiac function. However, it is not clear whether inflammatory cytokines or PPAR ligands regulate PPARs in the cardiomyocytes to modulate cardiac functions. We investigated the effects of tumour necrosis factor-alpha (TNF-α) and PPAR ligands on the expression of PPARs in HL-1 cardiomyocytes. Materials and methods: HL-1 cardiomyocytes were incubated with and without TNF-α (1, 10, 25 and 50 ng mL-1) or PPAR ligands (rosiglitazone, pioglitazone and fenofibrate) at concentrations of 0.1, 1 and 10 μm for 24 h. The cells also received SN-50 (NF-κB inhibitor, 50 μg mL-1), ascorbic acid (100 μm) and coenzyme Q10 (10 μm) alone or combined with TNF-α. Results: Using reverse transcriptase-polymerase chain reaction and Western blot, we found that incubation of TNF-α (50 ng mL-1) for 24 h decreased PPAR-α, but increased PPAR-γ without altering PPAR-δ. These effects were not changed by co-administration of SN-50. However, co-administration of ascorbic acid prevented the effect of TNF-α both on PPAR-α and PPAR-γ. Coenzyme Q10 partially attenuated the effect of TNF-α on PPAR-γ but did not alter its effect on PPAR-α. The administration of rosiglitazone (10 μm) and pioglitazone (10 μm) for 24 h increased PPAR-γ mRNA, but did not alter PPAR-α or PPAR-δ. Moreover, fenofibrate (0.1, 1 and 10 μm) increased PPAR-γ without any effects on PPAR-α or PPAR-δ. Conclusions: Oxidative stress causes the regulations of PPAR-α and PPAR-γ in the TNF-α-treated cardiomyocytes. The up-regulation of PPAR-γ by PPAR ligands may contribute to their anti-inflammation effects.",
keywords = "Ascorbic acid, Coenzyme Q, Peroxisome proliferator-activated receptors, Tumour necrosis factor-alpha",
author = "Lee, {T. I.} and Kao, {Y. H.} and Chen, {Y. C.} and Chen, {Y. J.}",
year = "2009",
month = "1",
doi = "10.1111/j.1365-2362.2008.02062.x",
language = "English",
volume = "39",
pages = "23--30",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors

AU - Lee, T. I.

AU - Kao, Y. H.

AU - Chen, Y. C.

AU - Chen, Y. J.

PY - 2009/1

Y1 - 2009/1

N2 - Background: Peroxisome proliferator-activated receptors (PPAR) mediate inflammatory processes and alter cardiac function. However, it is not clear whether inflammatory cytokines or PPAR ligands regulate PPARs in the cardiomyocytes to modulate cardiac functions. We investigated the effects of tumour necrosis factor-alpha (TNF-α) and PPAR ligands on the expression of PPARs in HL-1 cardiomyocytes. Materials and methods: HL-1 cardiomyocytes were incubated with and without TNF-α (1, 10, 25 and 50 ng mL-1) or PPAR ligands (rosiglitazone, pioglitazone and fenofibrate) at concentrations of 0.1, 1 and 10 μm for 24 h. The cells also received SN-50 (NF-κB inhibitor, 50 μg mL-1), ascorbic acid (100 μm) and coenzyme Q10 (10 μm) alone or combined with TNF-α. Results: Using reverse transcriptase-polymerase chain reaction and Western blot, we found that incubation of TNF-α (50 ng mL-1) for 24 h decreased PPAR-α, but increased PPAR-γ without altering PPAR-δ. These effects were not changed by co-administration of SN-50. However, co-administration of ascorbic acid prevented the effect of TNF-α both on PPAR-α and PPAR-γ. Coenzyme Q10 partially attenuated the effect of TNF-α on PPAR-γ but did not alter its effect on PPAR-α. The administration of rosiglitazone (10 μm) and pioglitazone (10 μm) for 24 h increased PPAR-γ mRNA, but did not alter PPAR-α or PPAR-δ. Moreover, fenofibrate (0.1, 1 and 10 μm) increased PPAR-γ without any effects on PPAR-α or PPAR-δ. Conclusions: Oxidative stress causes the regulations of PPAR-α and PPAR-γ in the TNF-α-treated cardiomyocytes. The up-regulation of PPAR-γ by PPAR ligands may contribute to their anti-inflammation effects.

AB - Background: Peroxisome proliferator-activated receptors (PPAR) mediate inflammatory processes and alter cardiac function. However, it is not clear whether inflammatory cytokines or PPAR ligands regulate PPARs in the cardiomyocytes to modulate cardiac functions. We investigated the effects of tumour necrosis factor-alpha (TNF-α) and PPAR ligands on the expression of PPARs in HL-1 cardiomyocytes. Materials and methods: HL-1 cardiomyocytes were incubated with and without TNF-α (1, 10, 25 and 50 ng mL-1) or PPAR ligands (rosiglitazone, pioglitazone and fenofibrate) at concentrations of 0.1, 1 and 10 μm for 24 h. The cells also received SN-50 (NF-κB inhibitor, 50 μg mL-1), ascorbic acid (100 μm) and coenzyme Q10 (10 μm) alone or combined with TNF-α. Results: Using reverse transcriptase-polymerase chain reaction and Western blot, we found that incubation of TNF-α (50 ng mL-1) for 24 h decreased PPAR-α, but increased PPAR-γ without altering PPAR-δ. These effects were not changed by co-administration of SN-50. However, co-administration of ascorbic acid prevented the effect of TNF-α both on PPAR-α and PPAR-γ. Coenzyme Q10 partially attenuated the effect of TNF-α on PPAR-γ but did not alter its effect on PPAR-α. The administration of rosiglitazone (10 μm) and pioglitazone (10 μm) for 24 h increased PPAR-γ mRNA, but did not alter PPAR-α or PPAR-δ. Moreover, fenofibrate (0.1, 1 and 10 μm) increased PPAR-γ without any effects on PPAR-α or PPAR-δ. Conclusions: Oxidative stress causes the regulations of PPAR-α and PPAR-γ in the TNF-α-treated cardiomyocytes. The up-regulation of PPAR-γ by PPAR ligands may contribute to their anti-inflammation effects.

KW - Ascorbic acid

KW - Coenzyme Q

KW - Peroxisome proliferator-activated receptors

KW - Tumour necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=57649198440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649198440&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2008.02062.x

DO - 10.1111/j.1365-2362.2008.02062.x

M3 - Article

C2 - 19067734

AN - SCOPUS:57649198440

VL - 39

SP - 23

EP - 30

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 1

ER -